ReviewAllergy2021
The global burden of illness of peanut allergy: A comprehensive literature review.
Review in Allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05138757 (Fiber Supplementation In Children With Peanut Allergy On Oral Immunotherapy), which is not on this map. Cited by 84 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fiber Supplementation In Children With Peanut Allergy On Oral Immunotherapy: A Randomized Controlled Pilot Study
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- Hypersensitivity to Intravenous Lipid Emulsions and Food Allergies: a Systematic Review of Case Reports.Current nutrition reports · 2026Pooled it
- Understanding the Variability of Peanut-Oral Immunotherapy Responses by Multi-Omics Profiling of Immune Cells.Allergy · 2025Trial
- Pragmatic Low-Dose Oral Immunotherapy for Preschool Children With Peanut Allergy: A Randomised Controlled Trial.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Trial
- Gut microbial bile and amino acid metabolism associate with peanut oral immunotherapy failure.Nature communications · 2025Trial
- Follow-up to Adolescence after Early Peanut Introduction for Allergy Prevention.NEJM evidence · 2024Trial
- Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.The Journal of allergy and clinical immunology · 2024Trial
- Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.The Journal of allergy and clinical immunology · 2023Trial
- Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy.The journal of allergy and clinical immunology. In practice · 2022Trial
- Common Food Emulsifiers Impair Epithelial Barrier Integrity and Trigger Pro-Inflammatory Responses and IgE Production.Allergy · 2026Article
- SAT1-Induced Spermidine Depletion Potentiates Food Allergy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Is age a critical factor for the diagnosis of peanut allergy in children?The World Allergy Organization journal · 2026Article
- Climate Change and Food Allergy: Adaptations and Risks at the Intersection of Environment and Health.Comprehensive reviews in food science and food safety · 2026Review
- Irradiation does not impact the immunogenicity of food flours used for oral immunotherapy.The journal of allergy and clinical immunology. Global · 2026Article
- Pediatric IgE mediated food allergies and ethnic group inequalities: A scoping review.The World Allergy Organization journal · 2026Review
- Peanut Oral Immunotherapy in Children: An Italian Single-Center Retrospective Cohort Study.Nutrients · 2026Article
- Differentiating Peanut Allergy from Sensitization in Polish Children: A Real-Life Diagnostic Model.Life (Basel, Switzerland) · 2026Article
- Decision Support Tools Strengthen Early Peanut Introduction Practices and Streamline Data Automation.Cureus · 2026Article
- Article
- CRISPR/Cas9 ribonucleoprotein-mediated knockout ofFrontiers in plant science · 2026Article
- Development and pilot validation of a chemiluminescence immunoassay for monitoring immunologic changes during peanut oral immunotherapy using sIgE/sIgG4 ratio.Frontiers in allergy · 2026Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peanut allergy (PA) currently affects approximately 2% of the general population of Western nations and may be increasing in prevalence. Patients with PA and their families/caregivers bear a considerable burden of self-management to avoid accidental peanut exposure and to administer emergency medication (adrenaline) if needed. Compared with other food allergies, PA is associated with higher rates of accidental exposure, severe reactions and potentially fatal anaphylaxis. Approximately 7%-14% of patients with PA experience accidental peanut exposure annually, and one-third to one-half may experience anaphylaxis, although fatalities are rare. These risks impose considerably high healthcare utilization and economic costs for patients with PA and restrictions on daily activities. Measures to accommodate patients with PA are often inadequate, with inconsistent standards for food labelling and inadequate safety policies in public establishments such as restaurants and schools. Children with PA are often bullied, resulting in sadness, humiliation and anxiety. These factors cumulatively contribute to significantly reduced health-related quality of life for patients with PA and families/caregivers. Such factors also provide essential context for risk/benefit assessments of new PA therapies. This narrative review comprehensively assessed the various factors comprising the burden of PA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.